Cargando…
Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study
BACKGROUND: Immunotherapy demonstrated remarkable efficacy in metastatic colorectal cancers (mCRCs) with mismatch repair deficiency (MMRd)/microsatellite instability (MSI). However, data regarding efficacy and safety of immunotherapy in the routine clinical practice are scarce. PATIENTS AND METHODS:...
Autores principales: | Alouani, E., Mercier, M., Flecchia, C., Auclin, E., Hollebecque, A., Mazard, T., Turpin, A., Pernot, S., Cohen, R., Dutherage, M., Kim, S., Sclafani, F., Ben-Abdelghani, M., Herve, C., Aparicio, T., De La Fouchardière, C., Perkins, G., Hautefeuille, V., Jaffrelot, M., Gallois, C., Bongard, V., Tougeron, D., Taïeb, J., Guimbaud, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265605/ https://www.ncbi.nlm.nih.gov/pubmed/37244250 http://dx.doi.org/10.1016/j.esmoop.2023.101574 |
Ejemplares similares
-
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015) -
Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in
first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO
multicentre study
por: Pernot, Simon, et al.
Publicado: (2018) -
Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
por: Bui, Quang Loc, et al.
Publicado: (2022) -
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
por: Palle, Juliette, et al.
Publicado: (2017) -
Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Pernot, Simon, et al.
Publicado: (2016)